Additionally, FIB-4 scores at the baseline and levels of IP-10 at the sixth year of the therapy were both higher in the group with prediabetes or T2DM, which indicates advanced hepatic fibrosis and increased inflammation. Here, CXCL10 is linked to prediabetes syndrome.